Establishing bepranemab posology through exposure‐response modeling and simulation for TOGETHER, a double‐blind, placebo‐controlled Phase II study of bepranemab in prodromal–mild Alzheimer’s disease (AD)

Exposure-response modeling and simulation of TOGETHER study data confirmed improvement in clinical outcomes with bepranemab in a prodromal-mild AD population with low tau burden or APOε4 non-carriers. The modeling also predicted that higher bepranemab doses are likely to be therapeutically beneficial (vs placebo) in future clinical trials.